A Study in Type II Diabetic Subjects of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Compound Alone and When Co-administered With Sitagliptin or Metformin .
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs GSK 1292263 (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 12 Jun 2012 Effects of GSK 1292263 on lipid parameters presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
- 28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
- 04 Jul 2010 New trial record